|
US6277975B1
(en)
|
1992-10-23 |
2001-08-21 |
Genetics Institute, Inc. |
Fusions of P-selectin ligand protein and polynucleotides encoding same
|
|
DE69934890D1
(de)
|
1998-06-16 |
2007-03-08 |
Univ Oklahoma |
Glykosulfopeptide und verfahren zu deren herstellung und deren verwendung
|
|
US7223845B2
(en)
|
1998-06-16 |
2007-05-29 |
The Board Of Regents Of The University Of Oklahoma |
Synthetic glycosulfopeptides and methods of synthesis thereof
|
|
US20030143662A1
(en)
|
1998-06-16 |
2003-07-31 |
Cummings Richard D. |
Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof
|
|
MXPA01004310A
(es)
*
|
1998-10-30 |
2003-06-06 |
Cbr Lab Inc |
Inhibicion de diferenciacion de celulas t citotoxicas mediante antagonistas de ligando de p-selectina (psgl).
|
|
CA2347940A1
(en)
*
|
1998-11-21 |
2000-06-02 |
The Regents Of The University Of California |
Use of core 2 glcnac transferase inhibitors in treating inflammation
|
|
US6492152B1
(en)
|
1999-06-15 |
2002-12-10 |
The Board Of Regents Of The University Of Oklahoma |
Core 1 β3-galactosyl transferases and methods of use thereof
|
|
US7256171B1
(en)
|
1999-11-20 |
2007-08-14 |
The Regents Of The University Of California |
Use of core 2 G1cNAc transferase inhibitors in treating inflammation
|
|
EP1325123A4
(en)
*
|
2000-09-12 |
2004-07-21 |
Inst Genetics Llc |
STENOSE- OR RESEARCH INHIBITION BY P-SELECTIN ANTAGONISTS
|
|
CA2433225A1
(en)
*
|
2000-12-29 |
2002-07-11 |
Bio-Technology General, Inc. |
Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
|
|
US20040116333A1
(en)
|
2001-08-03 |
2004-06-17 |
Rong-Hwa Lin |
Modulators of P-selectin glycoprotein ligand 1
|
|
US7744888B2
(en)
|
2001-08-03 |
2010-06-29 |
Abgenomics Cooperatief U.A. |
Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
|
|
WO2004012817A2
(en)
*
|
2002-07-31 |
2004-02-12 |
Kylix B.V. |
Use of genes identified to be involved in tumor development for the development of anti-cancer drugs
|
|
JP4599027B2
(ja)
*
|
2002-10-30 |
2010-12-15 |
東洋水産株式会社 |
Ｌ−セレクチン結合阻害剤
|
|
FI20021989A0
(fi)
*
|
2002-11-06 |
2002-11-06 |
Halina Miller-Podraza |
Korkean affiniteetin Helicobacter pylori-reseptorit ja niiden käyttö
|
|
GB0513881D0
(en)
|
2005-07-06 |
2005-08-10 |
Btg Int Ltd |
Core 2 GLCNAC-T Inhibitors III
|
|
US20080182801A1
(en)
|
2003-12-22 |
2008-07-31 |
Btg International Limited |
Core 2 glcnac-t inhibitors
|
|
GB0329667D0
(en)
|
2003-12-22 |
2004-01-28 |
King S College London |
Core 2 GlcNAc-T inhibitor
|
|
MY148646A
(en)
|
2004-05-10 |
2013-05-15 |
Abgenomics Cooperatief Ua |
Anti-psgl-1 antibodies
|
|
CN1985000B
(zh)
|
2004-05-11 |
2012-05-30 |
艾比吉诺米克斯合作公司 |
诱导t细胞死亡的表位
|
|
GB0513883D0
(en)
|
2005-07-06 |
2005-08-10 |
Btg Int Ltd |
Diagnosis of Atherosclerosis
|
|
GB0513888D0
(en)
|
2005-07-06 |
2005-08-10 |
Btg Int Ltd |
Core 2 GLCNAC-T Inhibitors II
|
|
WO2007067983A2
(en)
*
|
2005-12-09 |
2007-06-14 |
Wyeth |
Sulfotyrosine specific antibodies and uses therefor
|
|
JP5331293B2
(ja)
*
|
2006-04-28 |
2013-10-30 |
公益財団法人野口研究所 |
多様性を表現するオリゴ糖またはその誘導体
|
|
CN108947375B
(zh)
*
|
2008-09-02 |
2022-02-22 |
建筑研究和技术有限公司 |
包含增塑剂的硬化加速剂组合物
|
|
WO2011047794A2
(en)
*
|
2009-10-21 |
2011-04-28 |
Eth Zurich |
Medical utility of glycan-binding proteins and glycans
|
|
MX358447B
(es)
|
2011-06-13 |
2018-08-21 |
Abgenomics Cooeperatief U A Star |
Anticuerpos anti-psgl-1 y usos de los mismos.
|
|
EP3568159A4
(en)
|
2017-01-11 |
2020-08-05 |
Bristol-Myers Squibb Company |
PSGL-1 ANTAGONISTS AND THEIR USES
|
|
KR102715540B1
(ko)
|
2017-03-14 |
2024-10-08 |
파이브 프라임 테라퓨틱스, 인크. |
산성 pH에서 VISTA에 결합하는 항체
|
|
BR112020019083A2
(pt)
|
2018-03-21 |
2020-12-29 |
Five Prime Therapeutics, Inc. |
Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
|
|
BR112021000303A2
(pt)
|
2018-07-11 |
2021-04-13 |
Five Prime Therapeutics, Inc. |
Anticorpos que se ligam a vista em ph ácido
|